The U.S. National Institutes of Health recently confirmed it had initiated a multi-site, late-stage clinical trial evaluating an investigational antiviral for the treatment of COVID-19.
The therapeutic, known as S-217622 or ensitrelvir fumaric acid, was discovered by Hokkaido University, Sapporo, Japan, and Shionogi & Co., Ltd.
Read More
